Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer
Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer
Self-administered questionnaire survey to determine the presence or absence of joint pain
 during bevacizumab treatment for lung, ovarian, colorectal cancers.

 The principal end-point is the frequency of arthralgia after 6 months of treatment with
 Bevacizumab.
Inclusion Criteria:

 -  Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy

 -  Male or female (aged ≥18 years old)

 -  Performance Status (PS) between 0 and 2

 -  Expected life> 3 months

 -  Ability to answer a self-questionnaire

 -  Obtaining the non-opposition of patient participation

 Exclusion Criteria:

 -  Pregnant or lactating woman

 -  Rapid evolution of neoplastic pathology

 -  Major cognitive disorders that do not allow filling of the self-questionnaire

 -  Impossibility to submit to medical monitoring for social, psychological or
 geographical reasons

 -  Patients under guardianship or curatorship